in a nutshell
in a nutshell
DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel and commercially attractive therapeutic drug products.
DelSiTech provides the technology and expertise for solving drug delivery problems. The company’s technology is based on amorphous silica (SiO2) matrix and sol-gel encapsulation technique which have significant competitive advantages over other technologies.
In addition, the Company is developing its own pipeline of supergeneric/505(b)(2) products to address significant unmet medical and commercial needs. The lead product, a long acting antiviral product for hepatitis B, will enter the clinic in 2019.
Our partners come first. We appoint our top teams to all projects and we are committed to exceed expectations. Our virtues, trust and collaboration ensure close co-operation with biotech and pharma partners and the opportunity to adapt to all their needs.
We encourage an entrepreneurial culture that ensures that our teams are agile, innovative and produce high-quality solutions. We are guided by a long-term vision to provide the best solutions to our partners. Our stable business environment enables us to make long-term investments in all of our working relationships; we can be a continuous partner throughout the development of a product.
DelSiTech aims to become a significant player in the area of controlled release supergeneric/505(b)(2) product development. The Company has a growing pipeline of first-in-class and differentiated products with improved patient compliance. In addition, DelSiTech aims to become the partner of choice for biotech and pharma companies seeking for the best solution for their drug delivery needs.
The Company strategy is to 1) Partner and license its biodegradable silica based drug delivery technology to biotech and pharma industry companies, 2) Develop and commercialize the first in-house controlled release drug product for hepatitis B, and 3) Explore and identify other business opportunities for the silica technology with significant market potential to provide a continuous flow of novel products in the future.
DelSiTech has at its disposal a world-class organization that has successfully taken pharmaceutical and biomaterial products to the market.